Vengamamba Polu, MBBS

Vengamamba Polu practices at ECU Health Medical Center in Greenville, North Carolina, part of University Health Systems of Eastern Carolina.

Vengamamba Polu's NPI, 1982916342, was assigned on July 13, 2010. Vengamamba Polu holds North Carolina license 201301694.

Vengamamba Polu's primary practice is ECU Health Medical Center, at 2100 Stantonsburg Rd, Greenville, NC 27834 in Pitt County. The practice phone is (252) 847-4100.

Vengamamba Polu's primary practice is ECU Health Medical Center in Greenville, North Carolina, part of University Health Systems of Eastern Carolina. Vengamamba Polu is also affiliated with UNC Health Wayne. The medical group on file is ECU Health. Dmand AI also links Vengamamba Polu to 3 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Vengamamba Polu practices, 6 sites in all. Vendor and product names are available with a free account.

Endocrinology, diabetes and metabolism is Vengamamba Polu's primary specialty in the NPI Registry, under taxonomy code 207RE0101X. Vengamamba Polu is licensed in North Carolina.

CMS data shows 2,631 Medicare services from Vengamamba Polu across 16 procedure codes in 2024, for 318 Medicare patients. Medicare paid $104,011 for them. Every service was in an office.

CMS counts 318 Medicare patients who saw Vengamamba Polu in 2024. The largest group is 65 to 74, with 141 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 1.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Vengamamba Polu's median patient age at 69, with 69% women.

In 2024, Vengamamba Polu wrote 6,940 Medicare Part D claims for 717 patients. 24% of them were for generic drugs. CMS names the drug for 6,555 of them, across 67 drugs with 11 or more claims each, at $4,043,686 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Vengamamba Polu for performance year 2024, reported through an alternative payment model (APM). Vengamamba Polu accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 142 general payments to Vengamamba Polu from 24 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 99% of the total. Corcept Therapeutics paid the most, $376.